MiR-200b Inhibits Tumor Growth and Chemoresistance via Targeting p70S6K1 in Lung Cancer

Hui-Fang Jin*, Ju-Feng Wang2, Ting-Ting Song3, Jun Zhang4 and Lin Wang1,5*

Abstract: Downregulation of microRNA-200b (miR-200b) has been identified in a range of cancers, yet the specific mechanisms whereby it influences lung cancer growth require further exploration. We determined that lung cancer patient tumors exhibit decreased miR-200b expression, and we further found this miRNA to inhibit tumor growth via interfering with ERK1/2 and AKT signaling, targeting p70S6K1 to suppress HIF-1α expression. This miRNA further rendered H1299 cells more sensitive to cisplatin while impairing their proliferative and invasive potential through its ability to target and inhibit the activity of p70S6K1. These results were further confirmed in a murine xenograft model in which miR-200b also inhibited the growth of tumors and suppressed p70S6K1, p-AKT, p-ERK1/2, and HIF-1α expression. These findings clearly demonstrate a role for miR-200b in suppressing lung cancer development, making it a potentially relevant target for future diagnostic and therapeutic interventions.

Keywords: miR-200b, tumor growth, p70S6K1, chemoresistance, lung cancer

BACKGROUND

Lung cancers, of which up to 85% are non-small cell lung cancers (NSCLCs), remain one of the deadliest forms of cancer globally (1), with most NSCLC patients not being diagnosed until the disease is relatively advanced, resulting in almost 9 in 10 patients dying due to complications of tumor progression and metastasis (2). Indeed, this disease has just a 17% 5-year survival rate (3, 4). At present, patients with stage II or III NSCLC are typically treated through a combination of surgical tumor resection and cisplatin-based chemotherapy. Once NSCLC has metastasized, however, it tends to not be curable, as the tumors often exhibit intrinsic or acquired chemoresistance (5, 6). The specific mechanisms governing the development and progression of NSCLC remain to be completely characterized.

MicroRNAs (miRNAs) are short RNA molecules of roughly 22 nucleotides in length that lack coding potential (7). These miRNAs are known to regulate cancer cell proliferation, survival, and differentiation through control of particular signaling pathways within the cells (8). The miR-200 family is a group of miRNAs with an overlapping set of target genes and an identical seed sequence, with these miRNAs having been implicated in regulation of epithelial-to-mesenchymal transition (EMT) in tumor cells (9). Many cancers have been found to exhibit abnormal expression of miR-200 family miRNAs, as in the cases of gastric (10, 11), breast (12), bladder (13), and lung (14) cancers. Many miR-200b target genes have been
identified at present, such as VEGFR2, CDK2, KRAS, ZEB2, USP25, and UBQLN1 (15–20). Herein, we identify a novel role for miR-200b as an inhibitor of lung cancer growth and chemoresistance.

Herein, we were able to detect reduced miR-200b expression in tumors of human patients with lung cancer. We further explored the role of miR-200b in the growth and functionality of these lung cancer cells, identifying its target genes and exploring the effects of overexpression of this miRNA on lung cancer cell growth and chemoresistance. Together, these findings offer an opportunity to gain new insight into the mechanisms whereby lung cancer develops and progresses, potentially highlighting novel future therapeutic avenues for intervention.

**METHODS**

**Clinical Specimens**

A total of 56 paired normal and lung cancer tissue samples were collected at the First Affiliated Hospital of Zhengzhou University. Samples were snap frozen following surgical resection prior to analysis, with pathologists conducting histological analyses. All patients provided informed consent, and the institutional review board and ethics committees of Zhengzhou University approved this study.

**Cells and Reagents**

H1299 lung cancer cells were from American Type Culture Collection. Antibodies specific for p70S6K1, p-AKT, AKT, p-ERK1/2, and ERK1/2 were from Cell Signaling Technology (MA, USA), while those specific for GAPDH were from Bioworld Technology (GA, USA). Growth factor-reduced Matrigel came from BD Biosciences (MA, USA).

**RNA Analysis**

Trizol (Invitrogen, CA, USA) was used to extract total RNA based on provided directions, after which qPCR was used to measure miR-200b expression with U6 for normalization. For p70S6K1 expression measurements, GAPDH was used for normalization. A SYBR mix (Takara, Dalian, China) was used for all reactions, with expression changes calculated based on the 2^{−ΔΔCt} approach.

**Immunoblotting**

RIPA buffer containing protease inhibitors was used to lyse cells, and protein amounts were assessed via BCA assay (Beyotime, Jiangsu, China). Protein was separated by SDS-PAGE, transferred onto PVDF membranes (Roche, Switzerland), and assessed by Western blotting based on provided directions, using an ECL Detection System (Thermo Scientific, USA) to measure protein levels.

---

**FIGURE 1** | Lung tumors express reduced miR-200b levels. **(A)** Relative miR-200b expression levels were analyzed by Real-time RT-PCR in 56 pairs of lung tumor and adjacent healthy tissue, U6 RNA levels were used as an internal control. **(B)** Relative expression levels of miR-200b in cancer tissues at Grades I, II, and III-IV. **(C)** Expression of miR-200b was significantly lower in NSCLC patients with lymph node metastasis. Data are means ± SD. *P < 0.05; **P < 0.01.
**Cell Proliferation Assay**
Indicated miR-NC and miR-200b stable cell lines were plated for $2 \times 10^3$ cells per well. To evaluate the proliferation activity of miR-200b in lung cancer cells, according to the manufacturer's instruction, cell proliferation rate was analyzed with CCK-8 kit (Dojindo Laboratories, Japan).

**In vitro Invasion Assay**
Cellular invasion was determined with 24-well BD Matrigel invasion chambers (BD Biosciences, Cowley, UK) based on provided directions. Following a 16–24 h invasion period, cells that had not become invasive were removed via swabbing, and remaining cells were fixed in 3% paraformaldehyde prior to 0.1% crystal violet staining. Three independent fields were imaged, and OD570 was measured via microplate reader for triplicate samples.

**Dual-Luciferase Reporter Assay**
The region of the p70S6K1 3′-UTR containing the putative site for miR-200b binding was amplified and inserted in the pMIR-REPORTER vector (Ambion, CA, USA). Then, 24 h following transfection with these constructs, a Dual Luciferase Reporter Assay System (Promega, WI, USA) was used to assess luciferase activity. Experiments were repeated three times.

**Chemosensitivity Array**
A total of 4,000 cells were added in each well of a 96-well plate, and then after 24 h cisplatin (Sigma-Aldrich, MO, USA) was added after fresh preparation, for a final 1–40 µM concentration. After a further 48 h incubation, CCK-8 assay was used to assess viability.

**Flow Cytometry**
Apoptosis was assessed via staining cells with PE-Annexin V and propidium iodide (BD Pharmingen), followed by flow cytometry (FACS Canto II, BD Biosciences) analysis, with FlowJo used for data analyses.

**In vivo Tumor Growth**
Male nude mice (BALB/c-null, 6-week-old) from Shanghai Laboratory Animal Center (Chinese Academy of Sciences,
Shanghai, China) were used for all studies. Animals received a subcutaneous posterior flank injection with $5 \times 10^6$ tumor cells in a 150 uL total volume in serum-free RPMI-1640. Tumor growth was measured using calipers, and volume was determined based on the formula: volume = $0.5 \times (\text{Length} \times \text{Width}^2)$. After 28 days of tumor growth, animals were euthanized and tumors were isolated for weighing and western blotting. The Committee of Laboratory Animal Experimentation of Zhengzhou University approved all animal studies.

**Statistical Analysis**

GraphPad Prism 5 (CA, USA) was used for all analyses of triplicate experiments. Spearman’s rank test was used to assess correlations between the expression of miR-200b and p70S6K1. Other results were compared via t-tests, with $P < 0.05$ as the significance threshold.

**RESULTS**

**Lung Tumors Exhibit Reduced miR-200b Expression**

In this study, we began by measuring miR-200b expression via qRT-PCR in lung tumors and matched healthy control tissue samples (56 pairs), revealing significantly lower levels of this tumor in the tumor tissue specimens (Figure 1A). Tumors of WHO Grade III-IV also exhibited significantly reduced miR-200b leaves as compared with Grade I-II tumors, consistent with reduced expression of this miRNA in later stage disease (Figure 1B). We similarly found that there was significantly reduced miR-200b expression in NSCLC samples from patients with lymph node involvement than from those without such involvement (Figure 1C). These results thus suggest that reduced miR-200b expression may be a biomarker of advanced lung cancer progression.

![Figure 3](image-url)
miR-200b Overexpression Impaired Lung Cancer Cell Proliferation and Invasion

To investigate the function of miR-200b in lung cancer, we next generated H1299 lung cancer cells stably overexpressing miR-200b or NC control for in vitro analyses (Figure 2A). Using these cells, we found that miR-200b overexpression was associated with significantly reduced cell growth (Figure 2B).

We further investigated how changes in expression of this miRNA influenced colony formation and invasive activity in lung cancer cells, revealing that miR-200b overexpression significantly impaired both of these processes that are normally pronounced in lung cancer cells (Figures 2C,D). These findings therefore indicated that overexpressing miR-200b can impair the ability of lung cancer cells to proliferate and become invasive.

miR-200b Targets p70S6K1 to Disrupt AKT and ERK1/2 Signaling

We next utilized TargetScan (www.targetscan.org) as a means of identifying putative miR-200b targets, revealing a potential miR-200b binding site in the p70S6K1 3′-UTR (Figure 3A). We next used luciferase reporters bearing either the WT or mutated (MUT) version of this possible miR-200b binding sequence in the pMIR-REPORTER vector. These vectors were transfected into H1299 cells, revealing that miR-200b was able to significantly repress WT but not MUT reporter luciferase activity (Figure 3B). We further confirmed that miR-200b overexpressing cells exhibited reduced p70S6K1 protein levels (Figure 3C). Similarly, we found that tumor tissues from lung cancer patients exhibited significantly increased p70S6K1 relative to normal control samples (Figure 3D). Consistent with this, we found p70S6K1 and miR-200b expression to be negatively correlated in primary lung cancer samples (Figure 3E; Spearman’s $r = -0.5864$).

One key mechanism downstream of p70S6K1 is activation of PI3K/AKT and MAPK/ERK signaling, which play key roles in inducing tumor cell growth and induction of genes such as hypoxia-inducible factor-1α (HIF-1α). We found that cells overexpressing miR-200b exhibited markedly reduced p-AKT, p-ERK1/2, and HIF-1α levels relative to controls, whereas total AKT and ERK1/2 levels were unaffected (Figure 4A). To assess whether this effect was dependent upon p70S6K1, we overexpressed p70S6K1 in H1299 cells overexpressing miR-200b or miR-NC (for 48 h using the pCMV-p70S6K1 vector), revealing that this p70S6K1 overexpression was able to reverse this effect, increasing p-AKT, p-ERK1/2, and HIF-1α levels in miR-200b overexpressing cells. This thus indicated that miR-200b targets p70S6K1 to inhibit AKT and ERK signaling.
FIGURE 5 | miR-200b inhibits p70S6K1 to increase lung cancer cell cisplatin sensitivity. (A) H1299 cells stably expressing miR-NC or miR-200b were treated with different concentrations of cisplatin for 48 h, and cell viability was analyzed using CCK-8 assay; (B) H1299 cells stably expressing miR-NC, miR-200b, or miR-200b in combination with p70S6K1 overexpression were treated with 10 µM of cisplatin for indicated time points. Cell viability was analyzed by CCK-8 assay; (C) Cell apoptosis was analyzed by flow cytometry. Data are means ± SD. *P < 0.05, **P < 0.01 vs. control. #P < 0.05 vs. treatment with miR-200b and p70S6K1.

miR-200b Inhibits p70S6K1 to Suppress Cell Proliferation, Invasion and Chemoresistance

We next assessed the effects of miR-200b overexpression on H1299 cell functionality in a p70S6K1-dependent manner, revealing that overexpression of p70S6K1 in miR-200b-overexpressing cells restored their ability to proliferate and become invasive (Figures 4B,C).

Cisplatin resistance is a common cause of failed lung cancer chemotherapy, making it vital that novel means of increasing chemosensitivity be defined. Herein we found that miR-200b overexpression was linked to markedly elevated cisplatin chemosensitivity (Figure 5A). However, when p70S6K1 was overexpressed in these miR-200b overexpressing cells, this reversed their increased sensitivity to cisplatin (10 µM) as determined via CCK-8 assay (Figure 5B). To confirm the relevance of miR-200b and p70S6K1 to cisplatin-induced tumor cell apoptosis, rates of apoptotic death were assessed via flow cytometry, revealing that together miR-200b and cisplatin led to markedly elevated apoptosis rates, while additional p70S6K1 overexpression reversed the effect (Figure 5C). Together these findings suggested that miR-200b thus increases lung cancer cisplatin chemosensitivity, at least in part via targeting of p70S6K1.

miR-200b Inhibits in vivo Tumor Growth

To assess the importance of miR-200b in vivo in the context of tumor progression, we next injected mice with H1299 cells overexpressing either miR-200b or NC control and monitored tumor growth in these animals. Consistent with in vitro findings, miR-NC tumors grew significantly larger than miR-200b-overexpressing tumors (Figure 6A), and weighted significantly more (Figure 6B). In addition, the miR-200b-overexpressing tumors had reduced p70S6K1 levels relative to NC controls (Figures 6C,D). Furthermore, miR-200b was associated with reduced p-AKT, p-ERK1/2, and HIF-1α in excised tumor samples.
FIGURE 6 | MiR-200b inhibits in vivo tumor growth. (A,B) Male nude BALB/c mice were injected using $5 \times 10^6$ H1299 cells expressing elevated levels of either miR-200b or NC control. The volumes of tumors were monitored for 28 days, after which mice were sacrificed and tumors were weighed, revealing reduced tumor volume and weight in the context of miR-200b overexpression. (C) p70S6K1 mRNA levels in tumors overexpressing miR-200b were reduced relative to controls. (D) Reduced levels of p70S6K1, p-AKT, p-ERK1/2, and HIF-1α were evident in tumors overexpressing miR-200b relative to controls. Data are means ± SD. * $P < 0.05$; ** $P < 0.01$.

These results thus confirmed that miR-200b can target p70S6K1 and disrupt lung tumor growth in vivo.

DISCUSSION

Herein we gained novel insights into the role of miR-200b in lung cancer owing to its ability to suppress p70S6K1 expression. miRNAs are known to regulate cancer progression, and many studies have identified links between miRNA expression and patient clinical outcomes. For example, miR-33a-5p has been found to promote lung adenocarcinoma chemoresistance to celastrol owing to its ability to regulate the activity of mTOR (21). In addition, the upregulation of miR-93-5p was shown to be associated with enhanced NSCLC proliferation and poorer patient outcomes (22). Indeed, many studies have shown miRNAs to play assorted roles in the regulation of lung cancer cell proliferation and chemoresistance.

Herein we observed markedly decreased miR-200b levels in lung cancer tumor samples relative to healthy controls, consistent with previous results exhibiting reduced levels of this miRNA in other tumor types. For example, miR-200b can target FN1 to regulate EMT in breast cancer cells exhibiting chemoresistance (23), and it can similarly suppress the growth of esophageal squamous carcinoma cells, inducing their cell cycle arrest (24). This thus suggests that miR-200b can regulate target gene expression and cancer progression in multiple contexts.

In this study, we found that overexpression of miR-200b was sufficient to inhibit lung cancer cell proliferation, invasion, and colony formation. The miR-200 family is composed of 5 miRNA sequences: miR-200a, miR-200b, miR-200c, miR-141, and miR-429, which through the regulation of epithelial to mesenchymal transition (EMT) and cell proliferation to influence tumor growth in various cancers. We also tested miR-200a and miR-200c in lung cancer tissues, there are also downregulated in lung cancer tissues compared with normal tissues. Under this scope, we will conduct further investigation to evaluate their functions in the future, then make sure role of miR-200 family in lung cancer.

P70S6K1 is a gene capable of being regulated via mTOR signaling (25–27), and which is linked to vital cellular processes such as growth, maintenance of glucose levels, and protein
Herein we determined that this p70S6K1 oncogene was a direct miR-200b target, with an expression level negatively correlated with that of this miRNA in primary human samples. We additionally determined that miR-200b was able to suppress the activation of AKT and ERK1/2 as well as the expression of HIF-1α through its ability to target p70S6K1. These results together thus offer novel evidence in support of a model wherein miR-200b can suppress the growth of cells by inhibiting p70S6K1. While informative, these results do not preclude the possibility that the ability of miR-200b to target other genes also has an impact on lung cancer cell growth, and as such future studies exploring the clinical relevance of additional miR-200b targets are warranted.

Together these results indicate that miR-200b is capable of directly targeting p70S6K1, thereby suppressing lung cancer cell proliferation and invasion, suggesting that this miR-200b/p70S6K1 pathway could represent a novel mechanism governing tumor metastasis and may also serve as a valuable prognostic marker of disease progression.

**CONCLUSIONS**

In summary, our present investigation suggested that miR-200b functions as a tumor suppressor, as well as sensitizes lung cancer cells to CDDP treatment in an p70S6K1-dependent manner. Given its evident ability to impact metastasis and chemoresistance, the therapeutic value of miR-200b modulation is worthy of future exploration through experimental and clinical validation efforts.

**REFERENCES**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* (2011) 61:69–90. doi: 10.3322/caac.20107
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. *Science.* (2011) 331:1559–64. doi: 10.1126/science.1203543
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin.* (2010) 60:277–300. doi: 10.3322/caac.20073
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin.* (2013) 63:11–30. doi: 10.3322/caac.20116
5. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol.* (2008) 26:3552–9. doi: 10.1200/JCO.2007.13.9030
6. Stewart J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. *Citr Rev Oncol Hemotol.* (2010) 75:173–234. doi: 10.1016/j.critrevonc.2009.11.006
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer.* (2006) 6:857–66. doi: 10.1038/nrc1997
8. Pasquinelli E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. *Nat Rev Genet.* (2012) 13:271–82. doi: 10.1038/nrg3162
9. Park SM, Gaur AB, Lengel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev.* (2008) 22:894–907. doi: 10.1101/gad.1640608
10. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. *J Gastroenterol.* (2009) 44:556–61. doi: 10.1007/s00535-009-0037-7

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of Zhengzhou University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Ethics Committee of Zhengzhou University.

**AUTHOR CONTRIBUTIONS**

H-FJ and LW designed the study, analyzed data and drafted the manuscript. J-FW and T-TS participated in the manuscript preparation. H-FJ, LW, J-FW, T-TS, and JZ carried out the experiments *in vitro* and *in vivo*. All authors read and approved the final manuscript.

**FUNDING**

This study was supported by Key scientific research projects of universities in Henan Province (No. 18A310010) and the Science and Technology Research Project of Henan province (No. 192102310101).

11. Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. *Ann Surg Oncol.* (2012) 19(Suppl. 3):S656–64. doi: 10.1245/s10434-012-2217-6
12. Ye F, Tang H, Liu Q, Xie X, Wu M, Liu X, et al. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. *J Trans Med.* (2014) 12:17. doi: 10.1186/1479-5876-12-17
13. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. *Citr Cancer Res.* (2009) 15:5060–72. doi: 10.1158/1078-0432.CCR-08-2245
14. Ceppi P, Madduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. *Mol Cancer Res.* (2010) 8:1207–16. doi: 10.1158/1541-7786.MCR-10-0052
15. Jiao A, Sui M, Zhang L, Sun P, Geng D, Zhang W, et al. MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator. *Mol Med Rep.* (2016) 13:3349–55. doi: 10.3892/mmr.2016.4901
16. Kopp F, Wagner E, Roidl A. The proto-oncogene KRAS is targeted by miR-200c. *Oncotarget.* (2014) 5:185–95. doi: 10.18632/oncotarget.1427
17. Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F, et al. miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. *Mol Cancer.* (2014) 13:166. doi: 10.1186/1476-4598-13-166
18. Zhao X, Dou W, He L, Liang S, Tiej L, Liu C, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. *Oncogene.* (2013) 32:1363–72. doi: 10.1038/onc.2012.156
19. Sun Q, Liu T, Yuan Y, Guo Z, Xie G, Du S, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer. (2015) 136:1003–12. doi: 10.1002/ijc.29065

20. Wang X, Chen X, Han W, Ruan A, Chen L, Wang R, et al. miR-200c targets CDK2 and suppresses tumorigenesis in renal cell carcinoma. Mol Cancer Res. (2015) 13:1567–77. doi: 10.1158/1541-7786.MCR-15-0128

21. Li YJ, Sun YX, Hao RM, Wu P, Zhang JJ, Ma X, et al. miR-33a-5p enhances the sensitivity of lung adenocarcinoma cells to celastrol by regulating mTOR signaling. Int J Oncol. (2018) 52:1328–38. doi: 10.3892/ijo.2018.4276

22. Yang W, Bai J, Liu D, Wang S, Zhao N, Che R, et al. MiR-93–5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis. Gene. (2018) 647:13–20. doi: 10.1016/j.gene.2018.01.024

23. Yang X, Hu Q, Hu LX, Lin XR, Liu JQ, Lin X, et al. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. Discov Med. (2017) 24:75–85.

24. Zhang HF, Alshareef A, Wu C, Jiao JW, Sorensen PH, Lai R, et al. miR-200b induces cell cycle arrest and represses cell growth in esophageal squamous cell carcinoma. Carcinogenesis. (2016) 37:858–69. doi: 10.1093/carcin/bgw079

25. Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol. (2011) 43:47–59. doi: 10.1016/j.biocel.2010.09.018

26. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. (2010) 11:9–22. doi: 10.1038/nrm2822

27. Pretre V, Wicki A. Inhibition of Akt and other AGC kinases: a target for clinical cancer therapy? Semin Cancer Biol. (2018) 48:70–7. doi: 10.1016/j.semcancer.2017.04.011

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Jin, Wang, Song, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.